INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women, with a prevalence of 6 to 10% in the general population. Polycystic ovary syndrome is by far the most common cause of anovulatory infertility and has been reported to be associated with insulin resistance (IR), hyperinsulinemia, dyslipidemia, and central obesity, which are all risk factors for metabolic syndrome, type II diabetes mellitus, 1 and cardiovascular disease.
While the National Institutes of Health criteria from 1990 are strict and include only anovulation and hyperandrogenism, the Rotterdam consensus criteria of 2003 are broader and include polycystic ovarian morphology as a criterion. More recently, the Androgen Excess Society have proposed that hyperandrogenism should be mandatory for the diagnosis.
For many years, different combinations of clinical (irregular menstrual cycles, hirsutism and acne), biological [elevated serum testosterone or androstenedione levels or increased luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio], and ultrasound (U/S) criteria have been proposed with very little international consensus. The Rotterdam definition is wider, including many more women, the most notable ones being women without androgen excess. Critics say that findings obtained from the study of women with androgen excess cannot necessarily be extrapolated to women without androgen excess.
It has been proposed to include the U/S criteria in the definition of PCOS that are considered at the present to be the most specific, namely an increased ovarian volume (>10 mL) and/or presence of 12 or more follicles in each ovary measuring 2 to 9 mm. Indeed, using a threshold of 12 for the follicle number per ovary, 0.75% of PCOS patients were diagnosed, whereas 99% of the normal women were under this cutoff.
Metabolic disturbances are common in women suffering from PCOS: 30 to 40% have impaired glucose tolerance and IR with compensatory hyperinsulinemia, and as many as 10% will have type II diabetes mellitus 1, 4 by their fourth decade.
During the last decades, it has become evident that PCOS is more than just hirsutism and infertility. Most PCOS women are insulin resistant and have increased risk of hypertension, altered glucose metabolism, and probably increased lifetime risk of cardiovascular diseases. They have a higher prevalence of miscarriage, pregnancy-induced hypertension, preeclampsia, gestational diabetes mellitus, complicated deliveries, and preterm births; 30 to 50% of women with PCOS develop glucose intolerance or diabetes mellitus type II after the age of 30 years. The incidence is two-to threefold higher among women with PCOS compared with healthy women of similar age and body mass index (BMI).
Studies have found that one in two women with PCOS have a significant vitamin D deficiency, especially those who develop abdominal obesity. Links were also found between the degree of vitamin D deficiency and levels of the hormones, LH and FSH, which stimulate egg development. Lack of vitamin D may therefore be the missing link that explains why some women with PCOS develop worsening symptoms, while others are only mildly affected.
Current evidence suggested that IR has a central role in the pathogenesis of PCOS, 5 contributing to both metabolic and reproductive disturbances. Insulin resistance, i.e., impaired stimulation of glycogen formation in all major target tissues (skeletal muscle, adipose tissue, liver, kidney), is a pathogenic characteristic feature of PCOS, particularly among obese subjects. The molecular mechanisms of IR involve defects in the insulin-receptor signaling pathway in both adipocytes and skeletal muscle.
Insulin resistance causes compensatory hyperinsulinemia and might contribute to hyperandrogenism and gonadotropin aberrations through several mechanisms. Insulin may act directly in the hypothalamus, the pituitary, or both and thereby contribute to abnormal gonadotropin levels.
Recently, vitamin D deficiency has been proposed as the possible missing link between IR and PCOS. The European Union recommended intake is just 5 μg (200 IU) but this is based on calcium absorption for healthy bones. Many experts believe higher levels of at least 25 μg (1,000 IU) are needed for overall good health, especially when trying to conceive. The European Food Safety Authority has stated that the tolerable upper intake level for vitamin D (from all sources) is 100 μg/day (4,000 IU) for adults, including pregnant and lactating women. In PCOS, best is to measure vitamin D levels to assess the dose.
Recently, a lot of in vitro and in vivo studies have recognized several "noncalcemic" effects of vitamin D metabolites. Accumulating evidence suggests that the metabolic pathways of this vitamin may play a key role in developing gynecological/obstetric diseases. The VDR-mediated signaling pathways and vitamin D levels seem to deeply affect the risk of several gynecological diseases, such as PCOS, endometriosis, and ovarian and even breast cancer.
ASSOCIATION BETWEEN VITAMIN D STATUS AND METABOLIC DISTURBANCES IN PCOS IN OBSERVATIONAL STUDIES
Twelve studies had an observational design, employing a cross-sectional or case-control design, with vitamin D status as one of the preliminary outcomes. The studies included premenopausal women (14-50 years) of various ethnicities. Different stratifications were used: seven studies compared PCOS women with controls; three studies compared lean vs obese PCOS; one study compared PCOS women with and without the metabolic syndrome; and one study solely included PCOS women. 
EFFECT OF VITAMIN D SUPPLEMENTATION IN WOMEN WITH PCOS
Ten intervention trials had been carried out and published. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Among these, four had a randomized controlled trial design, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and one a case-control study design. 12 Different treatment protocols of vitamin D supplementation were used in the trials, varying from 400 IU a day in the trial carried out by Rashidi et al. 15 The followup duration ranged from 3 weeks to 6 months. In detail, JSAFOG the first study carried out in 1999 by Thys-Jacobs et al 17 among 13 PCOS women, who were treated with 50,000 IU ergocalciferol weekly or biweekly to achieve a target serum 25(OH)D level of 75-100 nmol/L, demonstrated an improvement in menstrual regularity and acne, and two women became pregnant in a follow-up period of 6 months. In addition, a more recent study carried out in Iran in fertile PCOS women has found an improvement in menstrual regularity after 3 months of supplementation with 1,000 mg/day calcium and 400 IU/day vitamin D.
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CORRELATION BETWEEN VITAMIN D STATUS, BMI, AND IR IN WOMEN WITH PCOS
Of the 29 reviewed studies, 18 examined the correlation between vitamin D status and IR in women affected by PCOS and reported the mean and/or median values and were therefore included in this analysis. Nine studies reported these values also for control women. 19, 20, [22] [23] [24] 27, 28, 41, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] The overall mean of serum 
CONCLUSION
In order to provide an overview of the relationship between vitamin D status and IR in women affected by PCOS compared with healthy control women, we carried out a regression analysis including serum 25(OH)D as an independent variable and HOMA-IR as a dependent variable.
Studies regarding vitamin D status in patients with PCOS show an inverse correlation between vitamin D levels and metabolic risk factors, e.g., IR, BMI, waist-tohip ratio, triglycerides, and a positive correlation with insulin sensitivity.
